Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Summit Therapeutics presents poster on Phase Out DMD clinical trial

The recently announced positive interim data from PhaseOut DMD showed that after 24 weeks of treatment, there was a significant and meaningful reduction in muscle damage, as well as a significant reduction in muscle inflammation, in patients treated with ezutromid
Test tubes
Summit has made a significant effort to ensure that biopsies from the trial are handled, processed and analysed with great care

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has been banging the drum at the 2018 MDA Clinical Conference in Arlington, Virginia, about its PhaseOut DMD clinical trial.

Summit stressed the scientific rigour of PhaseOut DMD, a Phase 2 open-label trial of the company's utrophin modulator, ezutromid, in patients with Duchenne muscular dystrophy (DMD).

READ: Summit Therapeutics shares jump on 'exciting' interim results of ezutromid study

Through this study, Summit is compiling a deep dataset for each patient in the trial, which includes the analysis of several thousand muscle fibres per biopsy sample.

As part of this effort, steps are being taken to remove human bias through the automated reading of biopsy and modified Rankin scale (MRS) measurements at central sites.

"Since DMD is a muscle-wasting disorder, it is critical for us to have high quality data from objective muscle health measurements as we assess ezutromid's activity.

As the collection of muscle biopsy and MRS measurements are a major intervention for patients in clinical trials, it means it is crucial this is done in a robust and reliable way," said Dr David Roblin, the chief medical officer and president of research & development at Summit.

READ: Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial

"Our data collection and analysis methods used in PhaseOut DMD helped yield a high-quality dataset from all evaluable boys in the trial after 24-weeks of treatment. We are grateful to all the boys in the trial and excited about the interim findings that showed compelling signs of ezutromid activity," Dr Roblin said.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use